Read by QxMD icon Read


Ryosuke Fujisawa, Yuji Akiyama, Takeshi Iwaya, Fumitaka Endo, Haruka Nikai, Shigeaki Baba, Takehiro Chiba, Toshimoto Kimura, Takeshi Takahara, Koki Otsuka, Hiroyuki Nitta, Masaru Mizuno, Keisuke Koeda, Akira Sasaki
BACKGROUND: Gastrointestinal stromal tumors (GISTs) grow relatively slowly and without specific symptoms; therefore, they are typically incidental findings. We report a rare gastric GIST in the mediastinum associated with chest discomfort and an esophageal hiatal hernia. CASE PRESENTATION: An 81-year-old woman with chest discomfort was admitted to the hospital, where barium esophagography showed a sliding esophageal hiatal hernia and a tumor of the lower esophagus and gastric wall...
December 13, 2018: Surgical Case Reports
Joshua B Brown, Reetesh K Pai, Melissa A Burgess, Jennifer Chennat, Amer H Zureikat
Gastrointestinal stromal tumors (GISTs) represent 1% of alimentary tract neoplasms. Up to 90% of GISTs are driven by activating mutations in tyrosine kinase KIT or PDGFR α genes. Imatinib mesylate is a tyrosine kinase inhibitor that has recently been used in a neoadjuvant role for locally advanced GIST. Pathologic complete response (pCR) to imatinib, however, is rare and may be limited to patients with certain mutations. We report on a 71-year-old woman with a large advanced gastric GIST near the gastroesophageal junction initially involving the pancreas, spleen, adrenal, and aortic wall...
December 2018: Journal of the National Comprehensive Cancer Network: JNCCN
Yugang Xu, Ming Cheng, Lei Mi, Yunping Qiu, Wenli Hao, Leping Li
Mir-22-3p is associated with many important biological processes, including neuroprotection, tumorigenesis, and various other tumor progressions. Our study aimed to investigate the roles of Mir-22-3p in chemosensitivity of gastrointestinal stromal tumor (GIST-T1) cells to cisplatin and explore its underlying mechanisms. Mir-22-3p high-expressing cell line was established by transfecting GIST-T1 cell line cells with Mir-22-3p mimic. After treatment with cisplatin (10 μM), Cell counting kits-8 (CCK-8) method was used to detect the cell viability...
August 12, 2018: Iranian Journal of Allergy, Asthma, and Immunology
Olli-Pekka Pulkka, Yemarshet K Gebreyohannes, Agnieszka Wozniak, John Patrick Mpindi, Olli Tynninen, Katherine Icay, Alejandra Cervera, Salla Keskitalo, Astrid Murumägi, Evgeny Kulesskiy, Maria Laaksonen, Krister Wennerberg, Markku Varjosalo, Pirjo M Laakkonen, Rainer Lehtonen, Sampsa Hautaniemi, Olli Kallioniemi, Patrick Schöffski, Harri Sihto, Heikki Joensuu
PURPOSE: Gastrointestinal stromal tumor (GIST) is a common type of soft tissue sarcoma. Imatinib, an inhibitor of KIT, PDFGRA and a few other tyrosine kinases, is highly effective for GIST, but advanced GISTs frequently progress on imatinib and other approved tyrosine kinase inhibitors. We investigated phosphodiesterase 3 (PDE3) as a potential therapeutic target in GIST cell lines and xenograft models. EXPERIMENTAL DESIGN: The GIST gene expression profile was interrogated in the MediSapiens IST Online transcriptome database comprising of human tissue and cancer samples, and PDE3A and PDE3B expression was studied using immunohistochemistry on tissue microarrays (TMAs) consisting of 630 formalin-fixed human tissue samples...
December 7, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
Yemarshet K Gebreyohannes, Elizabeth A Burton, Agnieszka Wozniak, Bernice Matusow, Gaston Habets, Jasmien Wellens, Jasmien Cornillie, Jack Lin, Marika Nespi, Guoxian Wu, Chao Zhang, Gideon Bollag, Maria Debiec-Rychter, Raf Sciot, Patrick Schöffski
The purpose of the present study was to investigate the in vitro and in vivo activity of PLX9486, a tyrosine kinase inhibitor (TKI) targeting both primary KIT exon 9 and 11 and secondary exon 17 and 18 mutations in gastrointestinal stromal tumors (GISTs). Imatinib, a potent inhibitor of mutated KIT, has revolutionized the clinical management of advanced, metastatic GIST. However, secondary resistance develops mainly through acquired mutations in KIT exons 13/14 or exons 17/18. Second-line sunitinib potently inhibits KIT exon 13/14 mutants but is ineffective against exon 17 mutations...
December 6, 2018: Clinical and Experimental Medicine
Changsong Qi, Fang Pan, Jian Li, Yanyan Li, Jing Gao, Lin Shen
OBJECTIVE: To investigate the biological behavior characteristics of gastrointestinal stromal tumors (GIST) with PDGFRA mutation and the patients' survival, and elucidate the efficacy of imatinib therapy. METHODS: Patients with PDGFRA D842V and non-D842V mutations were screened from a database of 1163 patients with GIST who were treated at Peking University Cancer Hospital from 2003 to 2018. Clinicopathological data of these patients were collected, including gender, age, tumor size, mitotic phase, primary position, metastatic site, and expressions of CD117, CD34, DOG-1...
November 25, 2018: Zhonghua Wei Chang Wai Ke za Zhi, Chinese Journal of Gastrointestinal Surgery
Jens Jakob, Peter Hohenberger
Introduction: Gastrointestinal stromal tumors (GIST) are rare malignant tumors in terms of incidence, and they are not linked to specific symptoms. Often, primary tumors, particularly of the stomach, rectum, or rectovaginal space, are quite large when detected, and multivisceral resection seems to be the treatment of choice as the mainstay of therapy is complete tumor removal. If a gain-of-function mutation in the KIT gene is present, drug therapy with receptor tyrosine kinase inhibitors (RTKIs) might significantly downstage primary GIST tumors...
October 2018: Visceral Medicine
Yuqing Tu, Rui Zuo, Nan Ni, Grant Eilers, Duolin Wu, Yuting Pei, Zuoming Nie, Yeqing Wu, Yuehong Wu, Wen-Bin Ou
Oncogenic KIT or PDGFRA receptor tyrosine kinase (TK) mutations are compelling therapeutic targets in gastrointestinal stromal tumors (GISTs), and the KIT/PDGFRA kinase inhibitor, imatinib, is the standard of care for patients with metastatic GIST. However, approximately 10% of KIT-positive GIST metastases lose KIT expression at the time of clinical progression during imatinib therapy. In the present report, we performed TK-activation screens, using phosphotyrosine-TK double immunoaffinity purification and mass spectrometry, in GIST in vitro models lacking KIT expression...
November 29, 2018: Cell Cycle
Zifeng Yang, Xingyu Feng, Peng Zhang, Tao Chen, Haibo Qiu, Zhiwei Zhou, Guoxin Li, Kai Xiong Tao, Yong Li
BACKGROUND: Till present, there are still controversies over the epidemiology, pathological features, types of surgical treatment, and prognoses of primary small gastric GISTs (gGISTs). METHODS: From January 1998 to January 2015, patients with primary small gGIST admitted from four high-volume medical centers of the Southern China were enrolled and their data were analyzed to evaluate their clinicopathological features, treatment and prognostic factors to provide evidence-based medical experience for clinical practice...
November 27, 2018: Surgical Endoscopy
Y X Feng, S Zhang, X J Xin
Objective: To investigate the ultrasonographic features of synchronous and heterochronic liver metastasis in patients with stromal tumors, and to elucidate the value of ultrasonic examination in follow-up surgery. Methods: A total of 1 516 patients with pathologically confirmed gastrointestinal stromal tumors (GISTs) and extra-gastrointestinal stromal tumors (EGISTs) were enrolled. The ultrasonographic features of primary lesions and liver metastases in a total of 46 cases with 95 liver metastases were analyzed...
November 23, 2018: Zhonghua Zhong Liu za Zhi [Chinese Journal of Oncology]
Yurie Futo, Shin Saito, Hideyo Miyato, Ai Sadatomo, Yuki Kaneko, Yoshihiko Kono, Daisuke Matsubara, Hisanaga Horie, Alan Kawarai Lefor, Naohiro Sata
INTRODUCTION: Duodenal gastrointestinal tumors (GISTs) are rare. Duodenal GISTs and pancreatic neuroendocrine tumors (NETs) may appear similar on imaging studies. GISTs arising from the second or third portions of duodenum may be incorrectly diagnosed as pancreatic NETs. PRESENTATION OF CASE: The patient is a 79-year-old man who was referred to our hospital with a history of tarry stools and loss of consciousness. Urgent upper digestive tract endoscopy revealed a bleeding submucosal duodenal lesion, which was controlled using endoscopic clips...
November 15, 2018: International Journal of Surgery Case Reports
Catarina Melo, Carolina Canhoto, Fernando Manata, António Bernardes
INTRODUCTION: Gastrointestinal stromal tumors represent about 1% of the tumors of digestive tract. Their presentation consists often of indolent symptoms. However, they can present as surgical emergencies in rare cases. This work presents a case of a giant jejunal GIST that required emergent surgical treatment. CASE PRESENTATION: A 60-year-old male presented with abdominal pain and acute low gastrointestinal bleeding. During observation a palpable mass was detected in the periumbilical region, left hypochondrium and left flank...
November 16, 2018: International Journal of Surgery Case Reports
Lin-Hai Yan, Zhi-Ning Chen, Chun-Jun Li, Jia Chen, Yu-Zhou Qin, Jian-Si Chen, Wei-Zhong Tang
Background: Imatinib has been regarded as the first successful synthetic small molecule targeting at blocking tyrosine kinase. Its high efficacy stabilized disease in above 80% of chronic myeloid leukemia (CML) patients over 10 years survival. Due to the similar canceration of gastrointestinal stromal tumor (GIST) as to CML, imatinib has been approved to be used as first-line treatment. Study design: Our retrospective study was proposed to enroll 191 GIST patients with larger tumor size (≥8 cm) who preoperative accepted imatinib from those with direct operation...
2018: Journal of Cancer
Sen Liu, Hongyu Liu, Yunlong Dong, Fengbiao Wang, Huijuan Wang, Jun Chen
Gastric carcinoma (GC) with gastrointestinal stromal tumor (GIST) is encountered very rarely in the clinic, and few cases have been reported in the literature. Here, we present a case involving a 72-year-old man who was diagnosed with gastric antrum adenocarcinoma accompanied by neuroendocrine differentiation and a GIST in the fundus, according to a preoperative examination and postoperative pathology. The patient then underwent a distal radical gastrectomy and GIST resection. After the operation, the patient was administered combined chemo-radiotherapy and subsequently underwent a 9-month follow-up examination...
October 2018: Médecine Sciences: M/S
Chien-Feng Li, Ting-Ting Liu, Jui-Chu Wang, Shih-Chen Yu, Yen-Yang Chen, Fu-Min Fang, Wan-Shan Li, Hsuan-Ying Huang
The lipid-metabolizing enzymes remain underexplored in gastrointestinal stromal tumors (GISTs). Through transcriptomic reappraisal, hydroxysteroid 11-beta dehydrogenase-1 ( HSD11B1 ) was identified as a top-upregulated, progression-associated gene. To validate the clinical relevance of HSD11B1 , the informative results of Sanger sequencing ( n = 58), mRNA quantification by branched-chain DNA in situ hybridization assay ( n = 70), copy number assay by fluorescent in situ hybridization ( n = 350), and immunohistochemistry ( n = 350) were correlated with clincopathological variables, KIT/PDGFRA/BRAF genotypes, and disease-free survival (DFS)...
November 1, 2018: Journal of Clinical Medicine
Sarah A Almagharbi, Yara A Fayoumi, Taha A Abdel-Meguid, Ahmed Abdelsalam, Rana Y Bokhary, Raed A Azhar
Gastrointestinal stromal tumors (GISTs) that originate outside the GI tract are extremely uncommon. In this case report, we describe a GIST of primary origin in the prostate gland of an 84-year-old male who presented with severe urinary retention at King Abdulaziz University Hospital in Saudi Arabia. Diagnosis was based on patient history, radiological studies, pathologic findings, and immunohistochemical data. Digital rectal examination revealed a hugely enlarged prostate encroaching upon the rectal lumen with a smooth and firm surface...
October 2018: Urology Annals
Chandrajit P Raut, N Joseph Espat, Robert G Maki, Dejka M Araujo, Jonathan Trent, Toni Faith Williams, D Das Purkayastha, Ronald P DeMatteo
Importance: Three years of adjuvant imatinib mesylate therapy is associated with reduced recurrence rates and improved overall survival in patients with high-risk primary gastrointestinal stromal tumor (GIST) compared with patients who receive 1 year of treatment. The impact of a longer duration of therapy is unknown. Objective: To determine whether adjuvant treatment for primary GIST with imatinib for 5 years is tolerable and efficacious. Design, Setting, and Participants: This prospective, single-arm, phase 2 clinical trial (Postresection Evaluation of Recurrence-free Survival for Gastrointestinal Stromal Tumors With 5 Years of Adjuvant Imatinib [PERSIST-5]) included adult patients with primary GIST (expressing KIT) at 21 US institutions who underwent a macroscopically complete resection and were at intermediate or high risk of recurrence, defined as primary GIST at any site measuring 2 cm or larger with 5 or more mitoses per 50 high-power field or nongastric primary GIST measuring 5 cm or larger...
November 1, 2018: JAMA Oncology
Weili Yang, Kai Li, Jiren Yu, Chunhui Shou, Qing Zhang, Yanyun Hong, Jianyi Sun, Hang Yu, Yuan Gao, Qianyun Shen, Zhicheng Zhao, Shusen Zheng
AIM: The majority of available data on the clinical efficacy of sunitinib in patients with imatinib-resistant or -intolerant gastrointestinal stromal tumours (GISTs) are from studies of western populations. We investigated the clinical outcomes of imatinib dose escalation versus sunitinib in first-line imatinib-failure Asian GIST patients to further guide clinical treatment. METHODS: Patients received imatinib dose escalation and a shift to sunitinib (Group A) or a direct shift to sunitinib (Group B)...
October 22, 2018: Scandinavian Journal of Gastroenterology
Sami Akbulut, Felat Ciftci, Abuzer Dirican
Gastrointestinal stromal tumors (GISTs) are the most common non-epithelial (mesenchymal) tumors of the gastrointestinal tract. Although GISTs appear as solid and well-circumscribed lesions in most patients, they may also appear as solid- cystic (mixed) or pure cystic lesions due to reasons like intra-tumor hemorrhage and necrosis in a very small percentage of patients. Hence, cystic GISTs mostly lead to a diagnostic dilemma. In this paper we aimed to report a case of pure cystic giant GIST that was drained percutaneously twice after being misdiagnosed as a mesenteric cyst...
2018: Annali Italiani di Chirurgia
Sergei Boichuk, Aigul Galembikova, Pavel Dunaev, Ekaterina Micheeva, Elena Valeeva, Maria Novikova, Natalya Khromova, Pavel Kopnin
Dysregulation of the fibroblast growth factor (FGF)/fibroblast growth factor receptor (FGFR) signaling pathway is frequently observed in multiple human malignancies, and thus, therapeutic strategies targeting FGFs and FGFRs in human cancer are being extensively explored. We observed the activation of the FGF/FGFR-signaling pathway in imatinib (IM)-resistant gastrointestinal stromal tumor (GIST) cells. Furthermore, we found that the activation of FGFR signaling has a significant impact on IM resistance in GISTs in vitro...
October 15, 2018: Molecules: a Journal of Synthetic Chemistry and Natural Product Chemistry
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"